Focusing on GLP-1 receptors now has the FDA’s blessing as a option to deal with the fatty liver illness referred to as MASH with Novo Nordisk’s weekly injectable drug Wegovy turning into the second accredited therapy for this prevalent metabolic dysfunction.
In MASH, brief for metabolic dysfunction-associated steatohepatitis, the buildup of fats within the liver results in irritation and scarring of the organ, which known as fibrosis. In response to the FDA, an estimated 14.9 million adults within the U.S. have MASH and its prevalence is rising. The late Friday regulatory choice for Wegovy covers the therapy of adults whose MASH has led to moderate-to-severe fibrosis. These sufferers should not have MASH that has progressed to liver cirrhosis, essentially the most superior stage of the illness. Like its earlier approval in weight problems, Wegovy’s MASH approval covers use of the drug alongside food regimen and train.
The energetic ingredient in Wegovy is semaglutide, a peptide engineered to focus on and activate GLP-1 receptors within the intestine. This method promotes satiety and delays gastric emptying, serving to sufferers really feel full in order that they eat much less. This mechanism of motion supported the drug’s preliminary approval in weight problems. The best way Wegovy works to deal with MASH will not be totally understood, however decreasing physique fats is believed to contribute to liver profit. Approval of the two.4 mg dose of Wegovy in MASH is predicated on interim outcomes from a placebo-controlled Section 3 medical trial evaluating 1,197 sufferers with moderate-to-severe MASH. At week 72, leads to 800 trial individuals confirmed 63% achieved MASH decision and no worsening of fibrosis, a aim achieved by 34% of these within the placebo arm.
The regulatory choice for Wegovy in MASH is an accelerated approval based mostly on the interim outcomes at 72 weeks. That profit have to be confirmed by the continued Section 3 trial. Investigators will look to see whether or not the irritation and scarring enhancements noticed on the interim 72-week mark translate into decreases in loss of life, liver transplants, and different liver-related occasions measured at 240 weeks.
Wegovy was accredited for treating weight problems in 2021. Final yr, the drug expanded its U.S. and European approvals to incorporate decreasing the chance of heart problems, coronary heart assault, and stroke in adults with weight problems or chubby. Throughout all of Wegovy’s accredited makes use of, Novo Nordisk reported greater than 36.8 billion Danish krone (about $5.7 billion) in gross sales within the first half of this yr.
“The FDA’s conditional approval of Wegovy for the therapy of adults with noncirrhotic MASH marks a really pivotal milestone and a big step ahead for the MASH neighborhood and people looking for new choices,” Dave Moore, Novo Nordisk’s government vice chairman of U.S. Operations stated in a ready assertion.
With its newest FDA approval, Wegovy will now compete in opposition to Rezdiffra, the Madrigal Prescribed drugs drug whose accelerated approval final yr made it the primary MASH drug. The small molecule, formulated as a once-daily capsule, works by focusing on and activating a receptor within the liver referred to as thyroid hormone receptor beta (THR-beta), mediating metabolic exercise within the organ. In Madrigal’s report of second quarter 2025 monetary outcomesthe corporate stated Rezdiffra accounted for greater than $350 million in income within the first half of this yr.
In a observe despatched to traders Saturday, Leerink Companions analyst Thomas Smith stated that whereas his agency believes medication like Wegovy will discover use treating some features of MASH, the agency expects drug mixtures spanning a number of drug lessons will change into the usual of look after this illness. Based mostly on discussions with clinicians, Smith stated Leerink expects incretin mimetics, together with Wegovy, are prone to be most well-liked for brand new MASH sufferers who’ve metabolic traits of the illness, similar to weight problems and heart problems, and who should not at the moment receiving medicine to handle these comorbidities.
Leerink nonetheless initiatives sturdy market uptake for Rezdiffra, with the Madrigal drug being most well-liked for sufferers who’re already taking a GLP-1 agonist. The agency notes that about 25% of sufferers taking Rezdiffra are additionally at the moment taking a GLP-1 drug and half of sufferers have tried a GLP-1 drug prior to now.
One other issue is the rising use of Eli Lilly’s tirzepatide, the GLP-1- and GIP receptor-targeting peptide marketed as Mounjaro for sort 2 diabetes and as Zepbound for weight administration. Smith stated it’s unlikely a doctor will swap a affected person already taking one in every of these Lilly medication to Novo Nordisk’s product merely due to its MASH approval. For these sufferers, Rezdiffra could be the drug of selection added on high of tirzepatide. That stated, Lilly is making ready to advance to Section 3 checks in MASH with tirzepatide and retatrutide, a peptide engineered to go after three targets.
For a few years, MASH (previously generally known as non-alcoholic steatohepatitis, or NASH) was a tricky indication for drug builders. Genfit and Intercept Prescribed drugs are among the many biotechs that encountered medical trial and regulatory setbacks within the metabolic illness. However Leerink’s Smith says the FDA nod for Wegovy in MASH, with a label in line with the drug’s medical trial expertise, bolsters confidence within the accelerated approval pathway for this indication. Leerink sees the most recent Wegovy approval having constructive readthrough to different medication in late-stage improvement for MASH.
Akero Therapeutics is at the moment in Section 3 testing with efruxifermin, a fusion protein engineered to imitate FGF21, a protein within the physique referred to as that regulates power expenditure and fats metabolization. The biotech has already reported Section 2 outcomes exhibiting this once-weekly injection met trial objectives exhibiting enchancment on measures of MASH at 96 weeks. Extra detailed outcomes have been revealed final week within the journal The Lancet. 89bio can also be in Section 3 testing with pegozafermin, an engineered model of FGF21. Sagimet Biosciences takes a distinct method with denifanstat, an oral small molecule inhibitor of fatty acid synthase (FASN).
“Transferring ahead, we’re inspired with FDA’s label consistency, well timed nature of accelerated approvals, and more and more progressive views on noninvasive checks (NITs) —all of that are remodeling the perceived issue of the regulatory path, in addition to the medical and business MASH panorama,” Smith stated.
Photograph: Michael Siluk/UCG/Common Photographs Group, by way of Getty Photographs
